Biomedical Genomics news

<p>Researchers of the Biomedical Genomics Laboratory</p>
6 Feb 2020

Various media channels have reported on the Pan-Cancer Project, which has involved the Biomedical Genomics Lab at the Institute for Research in Biomedicine (IRB Barcelona). 

The journal Nature has published a set of 23 articles that describe the most comprehensive genomic map of 38 types of cancer to date.  “It’s the first time that the complete genomes of tumours has been sequenced,” says Abel González, researcher in IRB Barcelona’s Biomedical Genomics Lab.

SER radio station has also interviewed Núria López-Bigas, head of the aforementioned lab. The researcher explains that one of the conclusions of the study is that “cancer is a genetic disease—a disease...

<p>The Pan-Cancer project showed that there is a molecular clock in our cells. (Rayne Zaayman-Gallant/EMBL)</p>
5 Feb 2020
  • Pan-Cancer Project discovers causes of previously unexplained cancers, pinpoints cancer-causing events and zeroes in on mechanisms of development
  • IRB Barcelona researchers, as part of an international team, contribute to the most comprehensive study of whole cancer genomes to date, significantly improving our fundamental understanding of cancer and signposting new directions for its diagnosis and treatment.
<p>Núria López-Bigas, head of the Biomedical Genomics Lab at IRB Barcelona, at the presentation ceremony of the ‘Doctores Diz Pintado’ National Cancer Prize</p>
29 Jan 2020

Several media have reported on the presentation ceremony of the ‘Doctores Diz Pintado’ National Cancer Prize, in which Núria López-Bigas, head of the Biomedical Genomics Lab at IRB Barcelona, received her award. During the event, López-Bigas called for all political parties to sign "a national pact for science involving long-term decisions". 

According to the scientist, "Governments are in power for short period of time, 4 years at the most, but science is a long-term national and social investment and it must not be conditioned by which party is governing or if we have new elections”.

 

 

 

Link to:...

<p>Núria López-Bigas, head of the Biomedical Genomics Lab at IRB Barcelona</p>
28 Jan 2020

Each year the Fundación de Investigación del Cáncer de la Universidad de la Salamanca (FICUS) - Centro de Investigación del Cáncer (CIC) presents the 'Doctores Diz Pintado' Prize with the aim to promote and acknowledge the contribution of young Spanish researchers to Cancer Research.

<p>Núria López-Bigas, head of the Biomedical Genomics Lab at IRB Barcelona</p>
27 Jan 2020

The newspapers La Gaceta de Salamanca and Tribuna Universitaria have interviewed Núria López-Bigas, ICREA researcher and head of the Biomedical Genomics Lab at the Institute for Research in Biomedicine (IRB Barcelona), on the occasion of the award of the “Doctores Diz Pintado” Prize, which she will receive in person on 28 January.  López-Bigas is the first female scientist to be presented with this prize. Referring to this point, the researcher says, “It is an honour to receive the prize. Being the first woman to do so highlights just how much work has to be done to achieve equality with respect to appraisement and visibility”.

<p>ICREA researcher at IRB Barcelona, Núria López-Bigas</p>
23 Dec 2019

The newspaper La Vanguardia has reported on the award of the “Doctores Diz Pintado” National Cancer Research Prize, to  Núria López-Bigas ICREA researcher at the Institute for Research in Biomedicine (IRB Barcelona)  in recognition of her work on the accumulation of mutations in the genome. Referring to López-Bigas, the jury highlighted "the relevance and impact of her work, which focuses on genomics and has wide applications in personalised medicine."

Link to: La Vanguardia 

...
<p>To ensure adequate levels of proteins in the cell, a strict quality control system is responsible for tagging the proteins with ubiquitin for degradation. Francisco Martínez, IRB Barcelona.</p>
2 Dec 2019

Published in the journal Nature Cancer, the study analyses how genetic alterations in tumour cells prevent the correct degradation of the proteins involved in tumour development and growth, thereby leading to abnormal cell behaviour.

A machine-learning model has allowed the scientists to obtain the most extensive annotation of the ubiquitin-mediated protein degradation system.

The analysis proposes a potential new clinical approach for cancer through the inhibition of oncoproteins with impaired degradation systems.

<p>Erika Lopez, IRB Barcelona.</p>
25 Nov 2019

The newspaper La Tribuna de Albacete has interviewed IRB Barcelona researcher Erika López Arribillaga about a grant awarded to her on 24 September by the Spanish Association Against Cancer (AECC). López Arribillaga’s project aims to unravel the long-term effects of some chemotherapy treatments on colorectal cancer patients. 

 

Link to La Tribuna de Albacete

 

 

<p>Researchers at IRB Barcelona have identified these genetic footprints produced by some cancer treatments and have for the first time been able to calculate the genetic toxicity of some of these treatments. Claudia Arnedo, IRB Barcelona.</p>
25 Nov 2019

The newspapers El MundoLa Vanguardia and Diari Ara, the TV station TV3 and the radio stationsCatalunya Ràdio andRAC1, among other media, have echoed on a study by the Biomedical Genommics lab, headed by Núria López, published in Nature Genetics. The study has for the first time determined the genetic mutations caused by various therapies used to treat cancer. “Studying the DNA damage caused by chemotherapies in patients’ cells is the first step towards understanding the relation between these mutations and the long-term side effects of these treatments,” says Oriol Pich, PhD student at IRB Barcelona and first author of the...

<p>Researchers at IRB Barcelona have identified these genetic footprints produced by some cancer treatments and have for the first time been able to calculate the genetic toxicity of some of these treatments. Claudia Arnedo, IRB Barcelona.</p>
19 Nov 2019

Scientists at IRB Barcelona determine the genetic alterations in the cells of cancer patients caused by the main cancer therapies.

This is an important step towards understanding the long-term side effects and optimizing treatments against cancer.

The results have been published in the journal Nature Genetics.